Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 2:24 AM
Ignite Modification Date:
2025-12-25 @ 2:24 AM
NCT ID:
NCT07000734
Eligibility Criteria:
Participants must be residents of Illinois or Missouri and able to come to St. Louis offices in person.
Inclusion Criteria:
* Ages 50-70
* Able to come to the research center for testing and intervention visits.
* Sedentary (no moderate exercise and no more than 15-minutes per day of light exercise (confirmed via interview with participants)).
* BMI≥27 or Body Roundness index ≥6
* Able to provide informed consent.
Exclusion Criteria:
* Dementia or other clinical neurodegenerative illness (e.g., Parkinson's disease, cerebrovascular disease unless minor eg one lacunar infarct with minimal/no impairment) per self-report or medical records.
* Medical conditions that suggest shortened lifespan (such as metastatic cancer), severe/uncontrolled psychiatric disorders or conditions that would prohibit safe participation.
* Unable to perform study assessments.
* Alcohol or substance abuse within 6 months per self-report or medical records.
* Concurrent cognitive training, such as brain-training software, or other interventions expected to affect neuroplasticity.
* Any drug that interacts pharmacokinetically, or is contraindicated with study interventions (examples would include high-dose SSRI that should not be combined with vortioxetine)
* PI has discretion to exclude potential participants eg if their health status appears either too good or too poor to be amenable to intervention
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
50 Years
Maximum Age:
70 Years
Study:
NCT07000734
Study Brief:
Protocol Section:
NCT07000734